PMID- 35148340
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220225
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 2
DP  - 2022
TI  - Effect of trimetazidine on the functional capacity of ischemic heart disease 
      patients not suitable for revascularization: Meta-analysis of randomized 
      controlled trials.
PG  - e0263932
LID - 10.1371/journal.pone.0263932 [doi]
LID - e0263932
AB  - OBJECTIVE: To explore the effect of adding trimetazidine to other anti-anginal 
      drugs on the functional capacity of ischemic heart disease (IHD) patients not 
      suitable for revascularization when compared to first-line antianginal drugs 
      alone. METHODS: MEDLINE and EMBASE databases were searched for English-language 
      peer-reviewed randomized controlled trials (RCTs) comparing trimetazidine with 
      first-line antianginal drugs alone or with placebo in IHD patients not suitable 
      for revascularization and were included in this review. Quality of studies were 
      assessed using the Cochrane collaboration "risk of bias" tool. RESULTS: Six RCTs, 
      three were crossover studies. A total of 312 participants were included in this 
      review. Overall quality of studies was moderate. Two studies found improvement in 
      the 6-minute walking test (6-MWT) [standardized mean differences (SMD) 1.75; 95% 
      CI 1.35 to 2.14; p <0.001], and two trials found improvement in the Canadian 
      cardiovascular society (CCS) grading of angina class (SMD -1.37; 95% CI -1.89 to 
      -0.84) in the trimetazidine group. Three of the better-quality trials found no 
      increase in total exercise duration (TED) (SMD 0.34; 95% CI -0.10 to 0.78; p < 
      0.13). Significant heterogeneity was identified among trials describing outcomes 
      for the New York Heart Association (NYHA) functional classification and left 
      ventricular ejection fraction (LVEF %). CONCLUSION: Trimetazidine improve walking 
      time and angina severity in IHD patients not suitable for revascularization. Due 
      to the inconsistency of available evidence, RCTs targeting IHD patients with "no 
      option" to undergo coronary revascularization is required to clarify this review 
      question.
FAU - Ajabnoor, Alyaa
AU  - Ajabnoor A
AUID- ORCID: 0000-0001-5154-6183
AD  - Faculty of Pharmacy, Department of Pharmacy Practice, King Abdulaziz University, 
      Jeddah, Saudi Arabia.
FAU - Mukhtar, Amnah
AU  - Mukhtar A
AD  - Pharmaceutical Care Division, King Faisal Specialist Hospital and Research 
      Center, Jeddah, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220211
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Vasodilator Agents)
RN  - N9A0A0R9S8 (Trimetazidine)
SB  - IM
MH  - Cross-Over Studies
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy/physiopathology
MH  - Randomized Controlled Trials as Topic
MH  - Stroke Volume/drug effects
MH  - Trimetazidine/*therapeutic use
MH  - Vasodilator Agents/*therapeutic use
MH  - Walk Test
PMC - PMC8836318
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/02/12 06:00
MHDA- 2022/02/26 06:00
PMCR- 2022/02/11
CRDT- 2022/02/11 17:11
PHST- 2021/11/28 00:00 [received]
PHST- 2022/01/29 00:00 [accepted]
PHST- 2022/02/11 17:11 [entrez]
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2022/02/11 00:00 [pmc-release]
AID - PONE-D-21-37700 [pii]
AID - 10.1371/journal.pone.0263932 [doi]
PST - epublish
SO  - PLoS One. 2022 Feb 11;17(2):e0263932. doi: 10.1371/journal.pone.0263932. 
      eCollection 2022.